Advertisement

Breast Cancer Research and Treatment

, Volume 146, Issue 2, pp 401–409 | Cite as

Incident comorbidities and all-cause mortality among 5-year survivors of Stage I and II breast cancer diagnosed at age 65 or older: a prospective-matched cohort study

  • Jennifer H. Jordan
  • Soe Soe Thwin
  • Timothy L. Lash
  • Diana S. M. Buist
  • Terry S. Field
  • Reina Haque
  • Pamala A. Pawloski
  • Hans V. Petersen
  • Marianne N. Prout
  • Virginia P. Quinn
  • Marianne Ulcickas Yood
  • Rebecca A. Silliman
  • Ann M. Geiger
Epidemiology

Abstract

Five-year breast cancer survivors, diagnosed after 65 years of age, may develop more incident comorbidities than similar populations free of cancer. We investigated whether older breast cancer survivors have a similar comorbidity burden 6–15 years after cancer diagnosis to matched women free of breast cancer at start of follow-up and whether incident comorbidities are associated with all-cause mortality. In this prospective cohort study, 1,361 older 5-year early-stage breast cancer survivors diagnosed between 1990 and 1994 and 1,361 age- and health system-matched women were followed for 10 years. Adjudicated medical record review captured prevalent and incident comorbidities during follow-up or until death as collected from the National Death Index. Older 5-year breast cancer survivors did not acquire incident comorbidities more often than matched women free of breast cancer in the subsequent 10 years [hazard ratio (HR) 1.0, 95 % confidence interval (95 % CI) 0.93, 1.1]. Adjusted for cohort membership, women with incident comorbidities had a higher mortality rate than those without incident comorbidities (HR 4.8, 95 % CI 4.1, 5.6). A breast cancer history continued to be a hazard for mortality 6–15 years after diagnosis (HR 1.3, 95 % CI 1.1, 1.4). We found that older breast cancer survivors who developed comorbidities had an increased all-cause mortality rate even after adjusting for age and prevalent comorbidity burden. Additionally, survivors acquire comorbidities at a rate similar to older women free of breast cancer. These results highlight the association between comorbidity burden and long-term mortality risk among older breast cancer survivors and their need for appropriate oncology and primary care follow-up.

Keywords

Breast cancer Survivorship Comorbidity Geriatrics Managed care Mortality 

Abbreviations

AJCC

American Joint Committee on Cancer

BOW

Breast Cancer Treatment Effectiveness in Older Women cohort study

CCI

Charlson Comorbidity Index

CI

Confidence interval

HR

Hazard ratio

mCCI

Modified Charlson Comorbidity Index

SEER

Surveillance, epidemiology, and end results

Notes

Acknowledgments

This study was funded by Public Health Service Grant R01CA093772 from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services (PI: RA Silliman). The funding sponsors played no part in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript. Sponsors had no access to the data and did not perform any of the study analysis.

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical standards

This study complies with the current laws of the United States of America. This study was reviewed and approved by the Institutional Review Boards of each participating institution and at the Boston University Medical Center.

References

  1. 1.
    Yancik R, Lag Ries (2000) Cancer and aging in America—demographic and epidemiologic perspectives. Hematol Oncol Clin N Am 14(1):17–23. doi: 10.1016/S0889-8588(05)70275-6 CrossRefGoogle Scholar
  2. 2.
    American Cancer Society (2011) Breast cancer facts & figures 2011–2012. American Cancer Society Inc., AtlantaGoogle Scholar
  3. 3.
    Smith BD, Jiang J, Mclaughlin SA, Hurria A, Smith GL, Giordano SH, Buchholz TA (2011) Improvement in breast cancer outcomes over time: are older women missing out? J Clin Oncol 29(35):4647–4653. doi: 10.1200/Jco.2011.35.8408 PubMedCrossRefGoogle Scholar
  4. 4.
    Van De Water W, Markopoulos C, Van De Velde CJ, Seynaeve C, Hasenburg A, Rea D, Putter H, Nortier JW, De Craen AJ, Hille ET, Bastiaannet E, Hadji P, Westendorp RG, Liefers GJ, Jones SE (2012) Association between age at diagnosis and disease-specific mortality among postmenopausal women with hormone receptor-positive breast cancer. J Am Med Assoc 307(6):590–597. doi: 10.1001/Jama.2012.84 Google Scholar
  5. 5.
    Pal SK, Hurria A (2010) Impact of age, sex, and comorbidity on cancer therapy and disease progression. J Clin Oncol 28(26):4086–4093. doi: 10.1200/Jco.2009.27.0579 PubMedCrossRefGoogle Scholar
  6. 6.
    Geraci JM, Escalante CP, Freeman JL, Goodwin JS (2005) Comorbid disease and cancer: the need for more relevant conceptual models in health services research. J Clin Oncol 23(30):7399–7404. doi: 10.1200/Jco.2004.00.9753 PubMedCentralPubMedCrossRefGoogle Scholar
  7. 7.
    Yancik R, Havlik RJ, Wesley MN, Ries L, Long S, Rossi WK, Edwards BK (1996) Cancer and comorbidity in older patients: a descriptive profile. Ann Epidemiol 6(5):399–412. doi: 10.1016/S1047-2797(96)00063-4 PubMedCrossRefGoogle Scholar
  8. 8.
    Guralnik JM (1996) Assessing the impact of comorbidity in the older population. Ann Epidemiol 6(5):376–380. doi: 10.1016/S1047-2797(96)00060-9 PubMedCrossRefGoogle Scholar
  9. 9.
    Jorgensen TL, Hallas J, Friis S, Herrstedt J (2012) Comorbidity in elderly cancer patients in relation to overall and cancer-specific mortality. Br J Cancer 106(7):1353–1360. doi: 10.1038/Bjc.2012.46 PubMedCentralPubMedCrossRefGoogle Scholar
  10. 10.
    Aziz NM, Rowland JH (2003) Trends and advances in cancer survivorship research: challenge and opportunity. Semin Radiat Oncol 13(3):248–266. doi: 10.1016/S1053-4296(03)00024-9 PubMedCrossRefGoogle Scholar
  11. 11.
    Hanchate AD, Clough-Gorr KM, Ash AS, Thwin SS, Silliman RA (2010) Longitudinal patterns in survival, comorbidity, healthcare utilization and quality of care among older women following breast cancer diagnosis. J Gen Intern Med 25(10):1045–1050. doi: 10.1007/S11606-010-1407-9 PubMedCentralPubMedCrossRefGoogle Scholar
  12. 12.
    Ahern TP, Lash TL, Thwin SS, Silliman RA (2009) Impact of acquired comorbidities on all-cause mortality rates among older breast cancer survivors. Med Care 47(1):73–79. doi: 10.1097/Mlr.0b013e318180913c PubMedCentralPubMedCrossRefGoogle Scholar
  13. 13.
    Enger SM, Thwin SS, Buist DS, Field T, Frost F, Geiger AM, Lash TL, Prout M, Yood MU, Wei F, Silliman RA (2006) Breast cancer treatment of older women in integrated health care settings. J Clin Oncol 24(27):4377–4383. doi: 10.1200/Jco.2006.06.3065 PubMedCentralPubMedCrossRefGoogle Scholar
  14. 14.
    Wagner EH, Greene SM, Hart G, Field TS, Fletcher S, Geiger AM, Herrinton LJ, Hornbrook MC, Johnson CC, Mouchawar J, Rolnick SJ, Stevens VJ, Taplin SH, Tolsma D, Vogt TM (2005) Building a research consortium of large health systems: the cancer research network. J Natl Cancer Inst Monogr 35:3–11. doi: 10.1093/Jncimonographs/Lgi032 PubMedCrossRefGoogle Scholar
  15. 15.
    Edge S, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A (2010) AJCC cancer staging manual, 7th edn. Springer, New YorkGoogle Scholar
  16. 16.
    Bosco JLF, Lash TL, Prout MN, Buist DSM, Geiger AM, Haque R, Wei FF, Silliman RA, Investigators B (2009) Breast cancer recurrence in older women five to ten years after diagnosis. Cancer Epidemiol Biomark 18(11):2979–2983. doi: 10.1158/1055-9965.Epi-09-0607 CrossRefGoogle Scholar
  17. 17.
    Thwin SS, Clough-Gorr KM, Mccarty MC, Lash TL, Alford SH, Buist DS, Enger SM, Field TS, Frost F, Wei F, Silliman RA (2007) Automated inter-rater reliability assessment and electronic data collection in a multi-center breast cancer study. BMC Med Res Methodol 7:23. doi: 10.1186/1471-2288-7-23 PubMedCentralPubMedCrossRefGoogle Scholar
  18. 18.
    Avila CC, Quinn VP, Geiger AM, Kerby TJ, St Charles M, Clough-Gorr KM (2011) Webinar training: an acceptable, feasible and effective approach for multi-site medical record abstraction: the BOWII experience. BMC Res Notes 4:430. doi: 10.1186/1756-0500-4-430 PubMedCentralPubMedCrossRefGoogle Scholar
  19. 19.
    Charlson ME, Pompei P, Ales KL, Mackenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40(5):373–383. doi: 10.1016/0021-9681(87)90171-8 PubMedCrossRefGoogle Scholar
  20. 20.
    Lash TL, Fox MP, Thwin SS, Geiger AM, Buist DS, Wei F, Field TS, Yood MU, Frost FJ, Quinn VP, Prout MN, Silliman RA (2007) Using probabilistic corrections to account for abstractor agreement in medical record reviews. Am J Epidemiol 165(12):1454–1461. doi: 10.1093/Aje/Kwm034 PubMedCrossRefGoogle Scholar
  21. 21.
    Adamo MB, Ruhl JL, Dickie LA (Ed) 2011 seer program coding and staging manual. National Cancer Institute, NIH publication number 11-5581, Bethesda, MDGoogle Scholar
  22. 22.
    Danese MD, O’malley C, Lindquist K, Gleeson M, Griffiths RI (2012) An observational study of the prevalence and incidence of comorbid conditions in older women with breast cancer. Ann Oncol 23(7):1756–1765. doi: 10.1093/Annonc/Mdr486 PubMedCentralPubMedCrossRefGoogle Scholar
  23. 23.
    Braithwaite D, Moore DH, Satariano WA, Kwan ML, Hiatt RA, Kroenke C, Caan BJ (2012) Prognostic impact of comorbidity among long-term breast cancer survivors: results from the lace study. Cancer Epidemiol Biomarkers Prev. doi: 10.1158/1055-9965.Epi-11-1228 PubMedCentralGoogle Scholar
  24. 24.
    Haque R, Yood MU, Geiger AM, Kamineni A, Avila CC, Shi J, Silliman RA, Quinn VP (2011) Long-term safety of radiotherapy and breast cancer laterality in older survivors. Cancer Epidemiol Biomark Prev 20(10):2120–2126. doi: 10.1158/1055-9965.Epi-11-0348 CrossRefGoogle Scholar
  25. 25.
    Steinherz LJ, Steinherz PG, Tan CT, Heller G, Murphy ML (1991) Cardiac toxicity 4 to 20 years after completing anthracycline therapy. J Am Med Assoc 266(12):1672–1677. doi: 10.1001/Jama.1991.03470120074036 CrossRefGoogle Scholar
  26. 26.
    Houterman S, Janssen-Heijnen MLG, Verheij CDGW, Louwman WJ, Vreugdenhil G, Van Der Sangen MJC, Coebergh JWW (2004) Comorbidity has negligible impact on treatment and complications but influences survival in breast cancer patients. Br J Cancer 90(12):2332–2337. doi: 10.1038/Sj.Bjc.6601844 PubMedCentralPubMedGoogle Scholar
  27. 27.
    Nagel G, Wedding U, Rohrig B, Katenkamp D (2004) The impact of comorbidity on the survival of postmenopausal women with breast cancer. J Cancer Res Clin Oncol 130(11):664–670. doi: 10.1007/S00432-004-0594-3 PubMedCrossRefGoogle Scholar
  28. 28.
    Patnaik JL, Byers T, Diguiseppi C, Denberg TD, Dabelea D (2011) The influence of comorbidities on overall survival among older women diagnosed with breast cancer. J Natl Cancer Inst 103(14):1101–1111. doi: 10.1093/Jnci/Djr188 PubMedCentralPubMedCrossRefGoogle Scholar
  29. 29.
    Sarfati D (2012) Review of methods used to measure comorbidity in cancer populations: no gold standard exists. J Clin Epidemiol. doi: 10.1016/J.Jclinepi.2012.02.017
  30. 30.
    Quan H, Li B, Couris CM, Fushimi K, Graham P, Hider P, Januel JM, Sundararajan V (2011) Updating and validating the Charlson Comorbidity Index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol 173(6):676–682. doi: 10.1093/Aje/Kwq433 PubMedCrossRefGoogle Scholar
  31. 31.
    Cabanillas ME, Lu H, Fang S, Du XL (2007) Elderly patients with non-Hodgkin lymphoma who receive chemotherapy are at higher risk for osteoporosis and fractures. Leuk Lymphoma 48(8):1514–1521. doi: 10.1080/10428190701471973 PubMedCrossRefGoogle Scholar
  32. 32.
    Chavez-Macgregor M, Zhao H, Kroll M, Fang S, Zhang N, Hortobagyi GN, Buchholz TA, Shih YC, Giordano SH (2011) Risk factors and incidence of thromboembolic events (TEEs) in older men and women with breast cancer. Ann Oncol 22(11):2394–2402. doi: 10.1093/Annonc/Mdq777 PubMedCentralPubMedCrossRefGoogle Scholar
  33. 33.
    Nekhlyudov L (2009) “Doc, should i see you or my oncologist?” A primary care perspective on opportunities and challenges in providing comprehensive care for cancer survivors. J Clin Oncol 27(15):2424–2426. doi: 10.1200/Jco.2008.21.4023 PubMedCrossRefGoogle Scholar
  34. 34.
    Cheung WY, Neville BA, Cameron DB, Cook EF, Earle CC (2009) Comparisons of patient and physician expectations for cancer survivorship care. J Clin Oncol 27(15):2489–2495. doi: 10.1200/Jco.2008.20.3232 PubMedCrossRefGoogle Scholar
  35. 35.
    Harlan LC, Klabunde CN, Ambs AH, Gibson T, Bernstein L, Mctiernan A, Meeske K, Baumgartner KB, Ballard-Barbash R (2009) Comorbidities, therapy, and newly diagnosed conditions for women with early stage breast cancer. J Cancer Surviv 3(2):89–98. doi: 10.1007/S11764-009-0084-3 PubMedCentralPubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Jennifer H. Jordan
    • 1
  • Soe Soe Thwin
    • 2
    • 3
  • Timothy L. Lash
    • 4
  • Diana S. M. Buist
    • 5
  • Terry S. Field
    • 6
  • Reina Haque
    • 7
  • Pamala A. Pawloski
    • 8
  • Hans V. Petersen
    • 9
  • Marianne N. Prout
    • 10
  • Virginia P. Quinn
    • 7
  • Marianne Ulcickas Yood
    • 10
  • Rebecca A. Silliman
    • 2
  • Ann M. Geiger
    • 11
  1. 1.Section on Cardiovascular Medicine, Department of Internal MedicineWake Forest School of MedicineWinston-SalemUSA
  2. 2.Section of Geriatrics, Boston Medical CenterBoston University School of MedicineBostonUSA
  3. 3.Massachusetts Veterans Epidemiology Research and Information Center (MAVERIC)VA Healthcare SystemJamaica PlainUSA
  4. 4.Department of EpidemiologyEmory University Rollins School of Public HealthAtlantaUSA
  5. 5.Group Health Research InstituteSeattleUSA
  6. 6.Meyers Primary Care InstituteWorcesterUSA
  7. 7.Department of Research and EvaluationKaiser Permanente Southern CaliforniaPasadenaUSA
  8. 8.HealthPartners Institute for Education and ResearchMinneapolisUSA
  9. 9.Lovelace Respiratory Research InstituteAlbuquerqueUSA
  10. 10.Department of EpidemiologyBoston University School of Public HealthBostonUSA
  11. 11.Health Services and Economics Branch (HSEB), Applied Research Program (ARP), Division of Cancer Control and Prevention (DCCPS)National Cancer Institute (NCI)RockvilleUSA

Personalised recommendations